Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
The Role of PCSK9 and Its Antagonism in Human Disease
share announcement

The Role of PCSK9 and Its Antagonism in Human Disease

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 3157

Special Issue Editor

Dr. Jae Hyun Byun

E-Mail Website
Guest Editor
Department of Medicine and Health Sciences, McGill University, Montréal, QC, Canada
Interests: lipid homeostasis; PCSK9; cholesterol-lowering

Special Issue Information

Dear Colleagues,

Since its seminal discovery in 2003, proprotein convertase subtilisin/kexin type-9 (PCSK9) has transcended from its initial role in lipid homeostasis into becoming a pivotal player in a wide range of human diseases. Initially identified for its role in regulating cholesterol levels by targeting low-density lipoprotein (LDL) receptors for degradation, PCSK9 inhibitors, including evolocumab and alirocumab, have revolutionized cardiovascular medicine as the next line of therapy in cholesterol lowering and provided new hope for patients with familial hypercholesterolemia.

Beyond lipid management, others have unveiled PCSK9's involvement in a myriad of diseases. This includes the modulation of the immune system, impacting inflammatory conditions such as rheumatoid arthritis and psoriasis. In neurology, PCSK9 inhibition shows promise for neurodegenerative disorders, such as Alzheimer's disease, by enhancing the clearance of amyloid-beta plaques. Moreover, cancer research has also embraced PCSK9 antagonism. Studies suggest its critical role in promoting tumor cell growth and migration, making PCSK9 a potential target for cancer therapies.

This Special Issue aims at compiling the most recent findings from PCSK9 inhibitor research and their intricate connections with human diseases that extend far beyond the realms of lipid homeostasis and atherosclerosis. Additionally, it will cover the role of PCSK9 in human cancers, neurodegenerative disorders, and the immune system's involvement in complex pathological inflammatory processes. We hope to provide a clear outline and a foundation for future research as we continue to unravel more roles of this multifaceted protein, potentially revolutionizing treatment strategies across cardiovascular medicine and beyond.

Dr. Jae Hyun Byun
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PCSK9
  • cholesterol
  • cardiovascular diseases
  • neurological diseases
  • human cancer
  • inflammation
  • anti-PCSK9 therapies
  • siRNA
  • monoclonal antibodies
  • genetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

19 pages, 5743 KiB  
Article
Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study
by Nitin Bharat Charbe, Flavia C. Zacconi, Venkata Krishna Kowthavarapu, Churni Gupta, Sushesh Srivatsa Palakurthi, Rajendran Satheeshkumar, Deepak K. Lokwani, Murtaza M. Tambuwala and Srinath Palakurthi
Biomedicines 2024, 12(2), 286; https://doi.org/10.3390/biomedicines12020286 - 26 Jan 2024
Cited by 2 | Viewed by 2775
Abstract
The primary cause of atherosclerotic cardiovascular disease (ASCVD) is elevated levels of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in this process by binding to the LDL receptor (LDL-R) domain, leading to reduced influx of LDL-C [...] Read more.
The primary cause of atherosclerotic cardiovascular disease (ASCVD) is elevated levels of low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in this process by binding to the LDL receptor (LDL-R) domain, leading to reduced influx of LDL-C and decreased LDL-R cell surface presentation on hepatocytes, resulting higher circulating levels of LDL-C. As a consequence, PCSK9 has been identified as a crucial target for drug development against dyslipidemia and hypercholesterolemia, aiming to lower plasma LDL-C levels. This research endeavors to identify promising inhibitory candidates that target the allosteric site of PCSK9 through an in silico approach. To start with, the FDA-approved Drug Library from Selleckchem was selected and virtually screened by docking studies using Glide extra-precision (XP) docking mode and Smina software (Version 1.1.2). Subsequently, rescoring of 100 drug compounds showing good average docking scores were performed using Gnina software (Version 1.0) to generate CNN Score and CNN binding affinity. Among the drug compounds, amikacin, bestatin, and natamycin were found to exhibit higher docking scores and CNN affinities against the PCSK9 enzyme. Molecular dynamics simulations further confirmed that these drug molecules established the stable protein–ligand complexes when compared to the apo structure of PCSK9 and the complex with the co-crystallized ligand structure. Moreover, the MM-GBSA calculations revealed binding free energy values ranging from −84.22 to −76.39 kcal/mol, which were found comparable to those obtained for the co-crystallized ligand structure. In conclusion, these identified drug molecules have the potential to serve as inhibitors PCSK9 enzyme and these finding could pave the way for the development of new PCSK9 inhibitory drugs in future in vitro research. Full article
(This article belongs to the Special Issue The Role of PCSK9 and Its Antagonism in Human Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop